Ernexa Therapeutics heads into its May 7 earnings report with two catalysts colliding at once — a 1-for-25 reverse stock split that went live May 4 and fresh preclinical data that briefly triggered a circuit breaker halt on Wednesday.
The borrow market tells the most striking story this week. Cost to borrow has nearly doubled in five days, jumping from roughly 165% APR to 395% APR — the sharpest weekly move in at least two months and now well above the 190% range that held for most of April. That spike is happening against an unusual backdrop: short interest as a percentage of float has collapsed, falling from around 2% to just 0.11% after the reverse split dramatically reduced the raw share count. Availability of shares to borrow is extraordinarily loose at over 1,900% of short interest, meaning there is no supply constraint on the lending side. The high cost, therefore, reflects demand-side pressure — what few shorts remain are paying a steep premium to hold those positions. The ORTEX short score jumped to 64.2 on May 5, up sharply from 41 where it had been anchored for most of April, signalling that the lending market has grown notably more stressed over the past two sessions even as absolute short exposure fell.
The reverse split is the mechanical explanation for much of this week's noise. Ernexa announced the 1-for-25 consolidation on April 30 and executed it on May 4. The share count compression accounts for the 94% week-on-week drop in estimated short shares and has distorted the near-term short interest trend almost entirely. What makes the lending picture genuinely unusual is that cost to borrow rose sharply the split — the opposite of what typically follows a reduction in borrow demand.
The preclinical news on May 6 added a separate, independent jolt. Ernexa announced that its ERNA-101 candidate achieved 100% long-term survival in syngeneic ovarian cancer models. The stock was halted on a downside circuit breaker before trading resumed sharply higher, closing May 5 at $3.99 — up 6.7% on the day but still down 16% on the week as the post-split price found its level. The one-month decline is 20%. With a market cap of approximately $4.7 million, this is a micro-cap biotech where any clinical headline carries outsized weight relative to the float.
Ownership is highly concentrated and worth flagging. Charles Cherington holds roughly 23% of shares and bought $2 million worth in February 2026 at $0.50 per pre-split share — implying a cost basis equivalent to $12.50 post-split. That is well above the current $3.99 price. The next three largest reported holders are individuals rather than institutions, with Freebird Partners and John Halpern at roughly 2.5% and 2.3% respectively. Vanguard and Geode each own fractional positions. The thin institutional base amplifies the volatility potential around any news flow.
Prior earnings prints have delivered mixed one-day reactions: +11.4% on March 31, -2.3% on March 13, and -0.6% and -1.2% at the two November 2025 events. The five-day drift has been consistently negative after three of the four most recent prints, ranging from -10% to -14%. The earnings event scheduled for May 7 — the day after the circuit-breaker halt and preclinical announcement — lands with the stock volatile, borrow costs spiking, and concentration risk elevated. How the market reconciles the ERNA-101 data against a pre-revenue, micro-cap balance sheet is the question heading into tomorrow's print.
See the live data behind this article on ORTEX.
Open ERNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
